期刊文献+

影响他克莫司浓度的药物遗传学研究进展 被引量:1

Progress in pharmacogenetic studies on effect on tacrolimus concentrations
下载PDF
导出
摘要 他克莫司药代动力学及药效动力学参数代谢个体差异大,治疗窗窄,是导致排斥或毒性反应的主要原因,其中遗传因素是引起他克莫司代谢个体差异的主要原因之一。本文就影响他克莫司血药浓度的遗传因素(主要包括代谢酶基因多态性及药物转运蛋白基因多态性)进行综述,从而为临床实现他克莫司个体化治疗提供参考。 The pharmacokinetic and pharmacodynamic parameters of tacrolimus have big individual differences,and the drug has a narrow treatment window.These are main causes leading to rejection and toxic reactions,and hereditary factors are one of main causes for individual difference of tacrolimus efficacy.In this paper,we review the hereditary factors which affect tacrolimus concentrations,mainly including metabolic enzyme gene polymorphism and dry delivery protein gene polymorphism,so as to provide reference for achievement of clinical individualized treatment with tacrolimus.
作者 杨爽 王力宁 YANG Shuang;WANG Li-ning(Department of Nephropathy,the First Hospital Affiliated to Chinese University of Medicine,Shenyang 110001,China)
出处 《临床肾脏病杂志》 2020年第9期752-757,共6页 Journal Of Clinical Nephrology
基金 国家自然科学基金(No.81370870)。
关键词 他克莫司 药物遗传学 基因多态性 CYP3A5 CYP3A4 Tacrolimus Pharmacogenetics Gene polymorphism CYP3A5 CYP3A4
  • 相关文献

参考文献1

二级参考文献20

  • 1Wang P, Mao Y, Razo J, et al. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients [J]. Pharmacogenomics, 2010, 11: 1389-1402.
  • 2Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus [J]. Clin Pharmacokinet, 1995, 29: 404-430.
  • 3Cattaneo D, Perico N, Remuzzi G From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosup- pressive therapy [J]. Am J Transplant, 2004, 4:299-310.
  • 4Staatz CE, Tett SE. Clinical pharmacokinetics and pharma- codynamics of tacrolimus in solid organ transplantation [J]. Clin Pharmacokinet, 2004, 43:623-653.
  • 5Qin XL, Chen X, Zhong GP, et al. Effect of Tacrolimus on the pharmacokinetics of bioactive lignans of Wuzhi tablet (Schisandra sphenanthera extract) and the potential roles of CYP3A and P-gp [J]. Phytomedicine, 2014, 21: 766-772.
  • 6Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients [J]. Clin Pharmacol Ther, 2007, 81 : 228-234,.
  • 7Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCBI) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels irt stable renal transplant patients [J]. Pharmacogenetics, 2004, 14:147- 154.
  • 8Zbao Y, Song M, Guan D, et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus [J]. Transplant Proc, 2005, 37: 178-181.
  • 9Li JL, Liu S, Fu Q, et al. Interactive effects of CYP3A4, CYP3A5, MDR1 and NRll2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients [J]. Pharmacogenomics, 2015, 16: 1355-1365.
  • 10van de Steeg E, Greupink R, Schreurs M, et al. Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATPIB1 [J]. Drug Metab Dispos, 2013,41:592- 601.

共引文献7

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部